⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13383282 | 0.84 | CA1 (0.37) | — | |
| SCHEMBL25472224 | 0.74 | — | — | |
| SCHEMBL1106717 | 0.74 | — | — | |
| SCHEMBL12121156 | 0.73 | CA1 (0.31) | — | |
| SCHEMBL14515499 | 0.70 | — | — | |
| SCHEMBL363653 | 0.70 | — | — | |
| SCHEMBL17305961 | 0.70 | — | — | |
| SCHEMBL12021992 | 0.67 | — | — | |
| SCHEMBL13606134 | 0.65 | — | — | |
| SCHEMBL31335579 | 0.65 | CA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11739269-B2 | Additive and application thereof | DAXIN MATERIALS CORPORATION (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2020008895-A1 | METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY ELEMENT | DIC株式会社 | 2020-01-09 | — | — | WO | disclosed |
| US-20180078518-A1 | Fixed Dose Combinations and Formulations Comprising ETC1002 and One or More Statins and Methods of Treating or Reducing Cardiovascular Disease | GLAS AMERICAS LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180064671-A1 | Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease | GLAS AMERICAS LLC | 2018-03-08 | — | — | US | disclosed |
| US-9855240-B2 | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2018-01-02 | — | — | US | disclosed |
| US-9849104-B2 | Treatment of NASH with gemcabene | GEMPHIRE THERAPEUTICS INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170172954-A1 | Treatment of NASH with Gemcabene | NEUROBO PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20150344389-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8497301-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120225908-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8153690-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | ESPERION THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2404890-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |